|
86 Companies |
|
137 Products |
|
137 Products |
|
85 Mechanisms of Action |
|
4 Trials |
|
2019 News |
|
| «12...1112131415161718192021...3940» |
- Adcetris (brentuximab vedotin) / Takeda, Pfizer
Enrollment change: Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin Lymphoma (clinicaltrials.gov) - Nov 3, 2014
P2, N=57, Recruiting, Sponsor: City of Hope Medical Center
N=37 --> 57
- ||||| bitopertin (DISC-1459) / Disc Medicine
Enrollment closed, Trial primary completion date: A Study of RO4917838 in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310) (clinicaltrials.gov) - Nov 3, 2014
P3, N=629, Active, not recruiting, Sponsor: Hoffmann-La Roche
N=37 --> 57 Completed --> Active, not recruiting | Trial primary completion date: May 2014 --> Jan 2015
- | risperidone controlled-release implant (BB-0817) / Braeburn
Trial completion: Study in Stabilized Schizophrenic Patients to Evaluate the Pharmacokinetics of Risperidone and 9-Hydroxy (OH)-Risperidone When Risperidone is Administered From a Polyurethane Implant (clinicaltrials.gov) - Nov 3, 2014
P1, N=35, Completed, Sponsor: Endo Pharmaceuticals
Completed --> Active, not recruiting | Trial primary completion date: May 2014 --> Jan 2015 Active, not recruiting --> Completed
- ||| Enrollment change: TURNS: Treatment Study for Cognitive Deficits in Schizophrenia (clinicaltrials.gov) - Oct 31, 2014
P2, N=63, Completed, Sponsor: University of California, Los Angeles
Active, not recruiting --> Completed N=90 --> 63
- Trial completion, Trial primary completion date: Brief Culturally Adapted Cognitive Behavior Therapy for Psychosis (clinicaltrials.gov) - Oct 30, 2014
P=N/A, N=120, Completed, Sponsor: Pakistan Association of Cognitive Therapists
N=90 --> 63 Recruiting --> Completed | Trial primary completion date: Dec 2013 --> Jul 2014
- ||||||| Abilify Maintena (aripiprazole extended release) / Otsuka, Lundbeck
Trial completion: Aripiprazole Once-monthly Versus Paliperidone Palmitate in Adult Patients With Schizophrenia (clinicaltrials.gov) - Oct 30, 2014
P3, N=296, Completed, Sponsor: H. Lundbeck A/S
Recruiting --> Completed | Trial primary completion date: Dec 2013 --> Jul 2014 Recruiting --> Completed
- | nelonicline (ABT-126) / AbbVie
Trial termination, Trial primary completion date: Long-term Safety and Efficacy of ABT-126 in Subjects With Schizophrenia: An Extension Study for Subjects Completing Study M10-855 (NCT01655680) (clinicaltrials.gov) - Oct 28, 2014
P2, N=268, Terminated, Sponsor: AbbVie
Recruiting --> Completed Active, not recruiting --> Terminated | Trial primary completion date: Aug 2015 --> Oct 2014; Study endpoint in preceding base study M10-855 not met.
- Clinical: Peer Support for Severe Mental Disorders (clinicaltrials.gov) - Oct 28, 2014
P=N/A, N=200, Active, not recruiting, Sponsor: Universitätsklinikum Hamburg-Eppendorf
- | ketamine / Generic mfg.
Trial completion, Trial primary completion date: The Effects of Ketamine and Guanfacine on Working Memory in Healthy Subjects (clinicaltrials.gov) - Oct 28, 2014
P=N/A, N=19, Completed, Sponsor: Yale University
Active, not recruiting --> Terminated | Trial primary completion date: Aug 2015 --> Oct 2014; Study endpoint in preceding base study M10-855 not met. Suspended --> Completed | Trial primary completion date: Aug 2013 --> Jul 2011
- Trial completion, Trial primary completion date: Patient Guided Psychiatric Admissions (clinicaltrials.gov) - Oct 28, 2014
P=N/A, N=53, Completed, Sponsor: St. Olavs Hospital
Suspended --> Completed | Trial primary completion date: Aug 2013 --> Jul 2011 Active, not recruiting --> Completed | Trial primary completion date: Jun 2014 --> Dec 2013
- ||| Trial completion: KUSS: Art Therapy in Acute Schizophrenia (clinicaltrials.gov) - Oct 24, 2014
P=N/A, N=60, Completed, Sponsor: Charite University, Berlin, Germany
Active, not recruiting --> Completed | Trial primary completion date: Jun 2014 --> Dec 2013 Recruiting --> Completed
- isradipine / Generic mfg.
Trial primary completion date: Evaluating Isradipine for Cognitive Enhancement in Schizophrenia and Schizoaffective Disorder (clinicaltrials.gov) - Oct 23, 2014
P=N/A, N=15, Recruiting, Sponsor: Katherine Burdick
Recruiting --> Completed Trial primary completion date: Sep 2014 --> Sep 2016
- Trial primary completion date: Cognitive Behavior Therapy and Work Outcome (clinicaltrials.gov) - Oct 23, 2014
P=N/A, N=120, Recruiting, Sponsor: Department of Veterans Affairs
Trial primary completion date: Sep 2014 --> Sep 2016 Trial primary completion date: Jun 2014 --> Jun 2015
- |||| Trial completion, Trial primary completion date: Cognitive Behavioral Therapy for Patients With an Early Psychosis (clinicaltrials.gov) - Oct 23, 2014
P2, N=60, Completed, Sponsor: Oslo University Hospital
Trial primary completion date: Jun 2014 --> Jun 2015 Active, not recruiting --> Completed | Trial primary completion date: Jan 2013 --> Oct 2014
- Trial primary completion date: CAST: Optimizing Cognitive Remediation Outcomes in Schizophrenia (clinicaltrials.gov) - Oct 22, 2014
P=N/A, N=80, Recruiting, Sponsor: University of California, San Francisco
Active, not recruiting --> Completed | Trial primary completion date: Jan 2013 --> Oct 2014 Trial primary completion date: Nov 2014 --> Apr 2015
- || Enrollment closed: Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants (clinicaltrials.gov) - Oct 22, 2014
P1, N=235, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Trial primary completion date: Nov 2014 --> Apr 2015 Recruiting --> Active, not recruiting
- ||||||| bitopertin (DISC-1459) / Disc Medicine
Trial completion, Trial primary completion date: A Study of RO4917838 in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310) (clinicaltrials.gov) - Oct 22, 2014
P3, N=629, Completed, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial primary completion date: Jan 2015 --> May 2014
- |||| bitopertin (DISC-1459) / Disc Medicine
Trial primary completion date: A Study of RO4917838 (Bitopertin) in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25305) (clinicaltrials.gov) - Oct 17, 2014
P3, N=601, Active, not recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed | Trial primary completion date: Jan 2015 --> May 2014 Trial primary completion date: May 2014 --> Dec 2014
- Trial primary completion date: Social Cognition Training in Schizophrenia (clinicaltrials.gov) - Oct 17, 2014
P=N/A, N=25, Recruiting, Sponsor: Oslo University Hospital
Trial primary completion date: May 2014 --> Dec 2014 Trial primary completion date: Dec 2012 --> Dec 2016
- | New P2 trial: Phase II Motivational Interviewing: An Experiential Online Training Tool (clinicaltrials.gov) - Oct 17, 2014
P2, N=3780, Not yet recruiting, Sponsor: Center for Social Innovation, Massachusetts
- | Enrollment open, Enrollment change: Therapeutic Efficacy of Transcranial Magnetic Stimulation in Schizophrenia (clinicaltrials.gov) - Oct 17, 2014
P2, N=30, Recruiting, Sponsor: Beth Israel Deaconess Medical Center
Trial primary completion date: Dec 2012 --> Dec 2016 Active, not recruiting --> Recruiting | N=14 --> 30
- || Enrollment closed: Oxytocin Treatment of Social Cognitive and Functional Deficits in Schizophrenia (clinicaltrials.gov) - Oct 17, 2014
P1, N=80, Active, not recruiting, Sponsor: University of North Carolina, Chapel Hill
Active, not recruiting --> Recruiting | N=14 --> 30 Recruiting --> Active, not recruiting
- Enrollment closed: Motivational Interviewing to Improve Work Outcomes in Schizophrenia (clinicaltrials.gov) - Oct 17, 2014
P3, N=48, Active, not recruiting, Sponsor: Department of Veterans Affairs
Recruiting --> Active, not recruiting Completed --> Active, not recruiting
- | RO5545965 / Roche
Trial completion: A Study of the Safety, Tolerability and Pharmacokientics of RO5545965 in Patients With Schizophrenia on Risperidone (clinicaltrials.gov) - Oct 17, 2014
P1, N=32, Completed, Sponsor: Hoffmann-La Roche
Completed --> Active, not recruiting Active, not recruiting --> Completed
- Trial completion, Trial primary completion date: tRNS in Anterior Cingulate Cortex Reduces Craving Over Dual Pathology Patients (clinicaltrials.gov) - Oct 17, 2014
P=N/A, N=225, Completed, Sponsor: Spanish Foundation for Neurometrics Development
Active, not recruiting --> Completed Not yet recruiting --> Completed | Trial primary completion date: Jan 2014 --> Aug 2014
- clonidine / Generic mfg., dronabinol oral / Generic mfg.
Trial primary completion date: Combination of Dronabinol and Clonidine for Cannabis Dependence in Patients With Schizophrenia (clinicaltrials.gov) - Oct 15, 2014
P2/3, N=18, Recruiting, Sponsor: Mclean Hospital
Not yet recruiting --> Completed | Trial primary completion date: Jan 2014 --> Aug 2014 Trial primary completion date: Jun 2014 --> Jun 2015
- ||| Byetta (exenatide) / AstraZeneca
Enrollment closed: Exenatide for the Treatment of Weight Gain Associated With Olanzapine in Obese Adults (clinicaltrials.gov) - Oct 15, 2014
P4, N=60, Active, not recruiting, Sponsor: University of Cincinnati
Trial primary completion date: Jun 2014 --> Jun 2015 Recruiting --> Active, not recruiting
- Trial completion: CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness (clinicaltrials.gov) - Oct 15, 2014
P=N/A, N=9500, Completed, Sponsor: Department of Veterans Affairs
Recruiting --> Active, not recruiting Recruiting --> Completed
- risperidone / Generic mfg.
Trial primary completion date: Study Of Talnetant Versus Placebo And Risperidone In Schizophrenia (clinicaltrials.gov) - Oct 11, 2014
P2, N=0, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Completed Trial primary completion date: Oct 2005 --> Jan 2009
- Clinical: Efficacy of Transitional Case Management Following Psychiatric Hospital Discharge (clinicaltrials.gov) - Oct 11, 2014
P=N/A, N=110, Completed, Sponsor: University of Lausanne Hospitals
- | Lu AF11167 / Lundbeck
New P1 trial: Pharmacokinetic Properties of Various Modified Release Tablet Formulations of Lu AF11167 (clinicaltrials.gov) - Oct 11, 2014
P1, N=28, Recruiting, Sponsor: H. Lundbeck A/S
- Lu AF11167 / Lundbeck
Enrollment open: Pharmacokinetic Properties of Various Modified Release Tablet Formulations of Lu AF11167 (clinicaltrials.gov) - Oct 11, 2014
P1, N=28, Recruiting, Sponsor: H. Lundbeck A/S
Trial primary completion date: Oct 2005 --> Jan 2009 Not yet recruiting --> Recruiting
- Trial completion: Efficacy of Transitional Case Management Following Psychiatric Hospital Discharge (clinicaltrials.gov) - Oct 11, 2014
P=N/A, N=110, Completed, Sponsor: University of Lausanne Hospitals
Not yet recruiting --> Recruiting Not yet recruiting --> Completed
- |||| Trial completion, Enrollment change: HOSPIPalm: A Study of Usage of Paliperidone Palmitate in Patients With Schizophrenia in a Hospital Setting (clinicaltrials.gov) - Oct 11, 2014
P4, N=372, Completed, Sponsor: Janssen-Cilag International NV
Not yet recruiting --> Completed Active, not recruiting --> Completed | N=13 --> 372
- Trial primary completion date: Transcranial Direct Current Stimulation (tDCS) and Hallucinations in Schizophrenia (clinicaltrials.gov) - Oct 10, 2014
P=N/A, N=60, Recruiting, Sponsor: H
Active, not recruiting --> Completed | N=13 --> 372 Trial primary completion date: Feb 2009 --> Sep 2015
- | PF-02545920 / Pfizer
Trial termination, Trial primary completion date: An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia (clinicaltrials.gov) - Oct 10, 2014
P2, N=239, Terminated, Sponsor: Pfizer
Recruiting --> Terminated | Trial primary completion date: Nov 2014 --> Aug 2014; A pre-planned interim analysis indicated the trial was unlikely to meet the pre-specified efficacy criteria. The decision was not based on any safety concerns.
- EVP6308 / Forum Pharmaceuticals
Enrollment open, Trial initiation date, Trial primary completion date: Study to Assess the Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Effects of EVP-6308 and the Potential of EVP-6308 to Affect the PK Properties of the Antipsychotic Regimen in Subjects With Schizophrenia Currently Receiving Stable Treatment With up to 2 Atypical Antipsychotics (clinicaltrials.gov) - Oct 10, 2014
P1, N=40, Recruiting, Sponsor: FORUM Pharmaceuticals Inc
The decision was not based on any safety concerns. Not yet recruiting --> Recruiting | Initiation date: Sep 2014 --> Jun 2014 | Trial primary completion date: Feb 2015 --> Nov 2014
- Enrollment closed, Trial primary completion date: Group Intervention for Improving Stigma Coping and Empowerment of People With Mental Illness (STEM) (clinicaltrials.gov) - Oct 10, 2014
P=N/A, N=512, Active, not recruiting, Sponsor: Wolfgang Gaebel, Professor
Not yet recruiting --> Recruiting | Initiation date: Sep 2014 --> Jun 2014 | Trial primary completion date: Feb 2015 --> Nov 2014 Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2014 --> Apr 2015
- Enrollment closed: Patient Guided Psychiatric Admissions (clinicaltrials.gov) - Oct 10, 2014
P=N/A, N=50, Active, not recruiting, Sponsor: St. Olavs Hospital
Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2014 --> Apr 2015 Recruiting --> Active, not recruiting
- | Doria (risperidone extended release) / ROVI Pharmaceuticals Laboratories
Trial completion: PRISMA-1: Pharmacokinetic, Safety, and Tolerability Study of Risperidone ISM (clinicaltrials.gov) - Oct 10, 2014
P1, N=36, Completed, Sponsor: Rovi Pharmaceuticals Laboratories
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- || Byetta (exenatide) / AstraZeneca
Trial primary completion date: Exenatide for the Treatment of Weight Gain Associated With Olanzapine in Obese Adults (clinicaltrials.gov) - Oct 4, 2014
P4, N=60, Recruiting, Sponsor: University of Cincinnati
Active, not recruiting --> Completed Trial primary completion date: Jul 2014 --> Nov 2014
- memantine ER / Generic mfg., galantamine extended release / Generic mfg.
Enrollment open: Galantamine and Memantine Combination for Cognitive Impairments in Schizophrenia (clinicaltrials.gov) - Oct 2, 2014
P2, N=10, Recruiting, Sponsor: Sheppard Pratt Health System
Trial primary completion date: Jul 2014 --> Nov 2014 Not yet recruiting --> Recruiting
- || Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
Trial primary completion date: A Study of Paliperidone Palmitate in Patients With Schizophrenia Previously Unsuccessfully Treated by Oral Antipsychotics (clinicaltrials.gov) - Sep 30, 2014
P4, N=617, Active, not recruiting, Sponsor: Xian-Janssen Pharmaceutical Ltd.
Not yet recruiting --> Recruiting Trial primary completion date: Jul 2014 --> Nov 2014
- Trial primary completion date: Acute Effects of Exercise in Smokers With Schizophrenia (clinicaltrials.gov) - Sep 30, 2014
P2, N=32, Recruiting, Sponsor: Brown University
Trial primary completion date: Jul 2014 --> Nov 2014 Trial primary completion date: Jan 2014 --> Jan 2015
- Trial initiation date, Trial primary completion date: Very Low Nicotine Cigarettes in Smokers With Schizophrenia (clinicaltrials.gov) - Sep 30, 2014
P2, N=80, Not yet recruiting, Sponsor: Brown University
Trial primary completion date: Jan 2014 --> Jan 2015 Initiation date: Jun 2014 --> Oct 2014 | Trial primary completion date: Jun 2016 --> Aug 2018
- encenicline (EVP-6124) / Forum Pharmaceuticals, Mitsubishi Tanabe
Trial primary completion date: Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy (clinicaltrials.gov) - Sep 29, 2014
P3, N=700, Recruiting, Sponsor: FORUM Pharmaceuticals Inc
Initiation date: Jun 2014 --> Oct 2014 | Trial primary completion date: Jun 2016 --> Aug 2018 Trial primary completion date: Nov 2014 --> Feb 2016
- encenicline (EVP-6124) / Forum Pharmaceuticals, Mitsubishi Tanabe
Trial primary completion date: Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy (clinicaltrials.gov) - Sep 29, 2014
P3, N=700, Recruiting, Sponsor: FORUM Pharmaceuticals Inc
Trial primary completion date: Nov 2014 --> Feb 2016 Trial primary completion date: Nov 2014 --> Feb 2016
- encenicline (EVP-6124) / Forum Pharmaceuticals, Mitsubishi Tanabe
Trial primary completion date: A 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy (clinicaltrials.gov) - Sep 29, 2014
P3, N=1050, Recruiting, Sponsor: FORUM Pharmaceuticals Inc
Trial primary completion date: Nov 2014 --> Feb 2016 Trial primary completion date: Oct 2015 --> Sep 2016
- ||||| lurasidone / Generic mfg.
Enrollment change: PEARL Schizophrenia Maintenance (clinicaltrials.gov) - Sep 28, 2014
P3, N=676, Completed, Sponsor: Sunovion
Trial primary completion date: Oct 2015 --> Sep 2016 N=285 --> 676
- || lurasidone / Generic mfg.
Trial primary completion date: High Dose Lurasidone for Patients With Treatment Resistant Schizophrenia (clinicaltrials.gov) - Sep 28, 2014
P4, N=120, Recruiting, Sponsor: Northwestern University
N=285 --> 676 Trial primary completion date: Dec 2014 --> May 2015